Vacaville, CA facility (Image courtesy of Roche)
March 20, 2024 05:35 AM EDTUpdated 06:46 AM
Manufacturing

Lon­za swoops in with $1.2B to take over Roche’s bi­o­log­ics site in Cal­i­for­nia

Reynald Castañeda

Deputy Editor

With Lon­za an­tic­i­pat­ing per­sis­tent in­crease in de­mand for com­mer­cial bi­o­log­ics man­u­fac­tur­ing, the Swiss com­pa­ny is pick­ing up a pro­duc­tion site owned by Roche’s Genen­tech for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Chi­nese drug­mak­er re­ceives FDA warn­ing let­ter af­ter man­age­ment hin­dered in­spec­tion

GSK plots reg­u­la­to­ry fil­ings for PBC itch af­ter pos­i­tive Phase 3 read­out

J&J, Pro­tag­o­nist re­veal two Phase 3 wins for oral IL-23 drug that's ex­pect­ed to be a block­buster

Bio­gen, UCB de­tail re­sponse rates in Phase 3 lu­pus tri­al af­ter sur­pris­ing suc­cess

Mer­ck fi­nal­ly has sub­cu­ta­neous Keytru­da re­sults, and it's go­ing to reg­u­la­tors

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times